Difference between revisions of "Plasma cell leukemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 11: Line 11:
  
 
=Untreated=
 
=Untreated=
 +
 +
==Ld {{#subobject:dc6eae|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
Ld: '''<u>L</u>'''enalidomide, low dose '''<u>d</u>'''examethasone
 +
 +
===Regimen {{#subobject:be34d7|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html Musto et al. 2013]
 +
|<span
 +
style="background:#eeee00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase II</span>
 +
|-
 +
|}
 +
 +
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
 +
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22
 +
 +
'''28-day cycle x 4 cycles'''
 +
 +
''Responding patients eligible for transplant proceeded to SCT per center protocol. Responding patients ineligible for transplant received 4 more cycles of Ld, followed by [[#Lenalidomide_.28Revlimid.29|lenalidomide maintenance]].''
 +
 +
===References===
 +
# Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. [http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23958922 PubMed]
  
 
==PAD/VCD {{#subobject:cc293b|Regimen=1}}==
 
==PAD/VCD {{#subobject:cc293b|Regimen=1}}==
Line 84: Line 116:
 
<!-- Presented at the 55th American Society of Hematology Annual Meeting, New Orleans, LA, December 7-10, 2013, and the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy, March 30 to April 2, 2014. -->
 
<!-- Presented at the 55th American Society of Hematology Annual Meeting, New Orleans, LA, December 7-10, 2013, and the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy, March 30 to April 2, 2014. -->
 
# Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/18/2125.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/27114594 PubMed]
 
# Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/18/2125.full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/27114594 PubMed]
 +
 +
==Lenalidomide (Revlimid) {{#subobject:bec321|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
 +
===Regimen {{#subobject:45c352|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|-
 +
|[http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html Musto et al. 2013]
 +
|<span
 +
style="background:#eeee00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase II</span>
 +
|-
 +
|}
 +
 +
''Treatment preceded by [[#Ld|Ld]] x 8.''
 +
 +
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21
 +
 +
'''28-day cycles until progression'''
 +
 +
===References===
 +
# Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. [http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23958922 PubMed]

Revision as of 13:00, 12 June 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site Are you looking for a regimen but can't find it here? It is possible that we've moved it to the obsolete regimens page. If you still can't find it, please let us know so we can add it!.

4 regimens on this page
4 variants on this page


Untreated

Ld

back to top

Ld: Lenalidomide, low dose dexamethasone

Regimen

Study Evidence
Musto et al. 2013 Phase II

28-day cycle x 4 cycles

Responding patients eligible for transplant proceeded to SCT per center protocol. Responding patients ineligible for transplant received 4 more cycles of Ld, followed by lenalidomide maintenance.

References

  1. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. link to original article contains verified protocol PubMed

PAD/VCD

back to top

PAD: PS-341 (Bortezomib), Adriamycin liposomal (Doxorubicin liposomal), Dexamethasone
VCD: Velcade (Bortezomib), Cyclophosphamide, Dexamethasone

Regimen

Study Evidence
Royer et al. 2016 Phase II

PAD portion

Two 21-day cycles (1 & 3), alternating with VCD

VCD portion

Two 21-day cycles (2 & 4), alternating with PAD

Responding patients proceeded to undergo high-dose melphalan & autologous stem cell transplant.

References

  1. Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains verified protocol PubMed

Consolidation after upfront therapy

Melphalan -> autologous stem cell transplant

back to top

Regimen

Study Evidence
Royer et al. 2016 Phase II

Treatment preceded by PAD alternating with VCD.

Chemotherapy

  • Melphalan (Alkeran) 200 mg/m2 IV once
    • Patients > 65 years or with CrCl < 30 mL/min received 140 mg/m2

References

  1. Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains protocol PubMed

Lenalidomide (Revlimid)

back to top

Regimen

Study Evidence
Musto et al. 2013 Phase II

Treatment preceded by Ld x 8.

28-day cycles until progression

References

  1. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Plasma_cell_leukemia&oldid=11185"